Ulcerative colitis (UC) is a chronic inflammatory disease of unknown etiology, primarily involving the colon and rectum. Characterized by recurrent episodes and prolonged disease course, UC requires dynamic monitoring and evaluation. Current commonly used methods for disease monitoring and assessment include C-reactive protein (CRP), fecal calprotectin (FC), and colonoscopy. However, CRP lacks specificity, FC fails to effectively differentiate UC from Crohn's disease, while colonoscopy involves complex bowel preparation, is invasive, and suffers from poor patient compliance. Therefore, there is an urgent clinical need to identify non-invasive biological markers with high sensitivity and specificity for the diagnosis and evaluation of UC. Recent studies have demonstrated that anti-integrin αvβ6 autoantibodies hold significant value in the diagnosis, differential diagnosis, and disease assessment of UC, potentially emerging as an important clinical biomarker. This article reviews the research progress of anti-integrin αvβ6 autoantibodies in UC for reference.

Ulcerative colitis (UC) is a chronic inflammatory disease of unknown etiology, primarily involving the colon and rectum. Characterized by recurrent episodes and prolonged disease course, UC requires dynamic monitoring and evaluation. Current commonly used methods for disease monitoring and assessment include C-reactive protein (CRP), fecal calprotectin (FC), and colonoscopy. However, CRP lacks specificity, FC fails to effectively differentiate UC from Crohn's disease, while colonoscopy involves complex bowel preparation, is invasive, and suffers from poor patient compliance. Therefore, there is an urgent clinical need to identify non-invasive biological markers with high sensitivity and specificity for the diagnosis and evaluation of UC. Recent studies have demonstrated that anti-integrin αvβ6 autoantibodies hold significant value in the diagnosis, differential diagnosis, and disease assessment of UC, potentially emerging as an important clinical biomarker. This article reviews the research progress of anti-integrin αvβ6 autoantibodies in UC for reference.

【Objective】 To investigate the situation of whole blood collection in Tianjin after COVID-19 prevention and control measures were fully lifted. 【Methods】 The relevant data on whole blood collection of voluntary blood donors in Tianjin 15 days before Spring Festival (2023.01.07-2023.01.21, when China has managed COVID-19 with measures against Class B infectious disease instead of Class A infectious diseases) and 15 days before Spring Festival in 2018 (2018.02.01- 2018.02.15) and 2019 (2019.01.21-2019.02.04) before the breakout of COVID-19 were retrospectively collected and compared. 【Results】 The comparison between the above period in 2023, 2018 and 2019 was as follows: the number of blood donors was 6 124 vs 3 940 vs 4 069; blood collection volume (U) was 9 623 vs 7 378 vs 7 808; the proportion of first-time blood donors, local blood donors and group blood donors was 69.17% (4 236/6 124) vs 65.86% (2 595/3 940) vs 62.05% (2 525/4 069), 59.31% (3 632/6 124) vs 23.27% (9170) vs 18.19% (740/4 069) and 43.42% (2 659/6 124) vs 8.05% (317/2 595) vs 0.15% (6/4 069) (all P<0.05). 【Conclusion】 The adjustment of COVID-19 prevention and control policy has a significant impact on voluntary blood donation, and the corresponding adjustment of blood donor recruitment strategy in blood centers should be conducted to increase the whole blood collection.

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. Fat accumulation "sensitizes" the liver to insult and leads to nonalcoholic steatohepatitis (NASH). G protein-coupled receptor 35 (GPR35) is involved in metabolic stresses, but its role in NAFLD is unknown. We report that hepatocyte GPR35 mitigates NASH by regulating hepatic cholesterol homeostasis. Specifically, we found that GPR35 overexpression in hepatocytes protected against high-fat/cholesterol/fructose (HFCF) diet-induced steatohepatitis, whereas loss of GPR35 had the opposite effect. Administration of the GPR35 agonist kynurenic acid (Kyna) suppressed HFCF diet-induced steatohepatitis in mice. Kyna/GPR35 induced expression of StAR-related lipid transfer protein 4 (STARD4) through the ERK1/2 signaling pathway, ultimately resulting in hepatic cholesterol esterification and bile acid synthesis (BAS). The overexpression of STARD4 increased the expression of the BAS rate-limiting enzymes cytochrome P450 family 7 subfamily A member 1 (CYP7A1) and CYP8B1, promoting the conversion of cholesterol to bile acid. The protective effect induced by GPR35 overexpression in hepatocytes disappeared in hepatocyte STARD4-knockdown mice. STARD4 overexpression in hepatocytes reversed the aggravation of HFCF diet-induced steatohepatitis caused by the loss of GPR35 expression in hepatocytes in mice. Our findings indicate that the GPR35-STARD4 axis is a promising therapeutic target for NAFLD.

Objective To improve the in vivo analgesic activity of acacetin and find leads for the development of new drugs, novel acacetin derivatives containing alkyl amide groups with different length of carbon chain were designed and synthesized according to the molecular structure of the active hit compound found in our previous work. Methods Using apigenin as the initial chemical ma-terial,the acacetin was synthesized through 3 steps,then the target compounds were prepared by conjugating hydroxy group of acace-tin at position 7 with bromoalkyl amides. The analgesic activity of the target compounds was evaluated by acetic acid writhing model of mice. Results and Conclusion Novel acacetin alkyl amide derivatives showed more potent analgesic activities than that of clinical medicine diclofenac,which could be used as leads for further development of new drugs.